{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:49:32Z","timestamp":1715586572878},"reference-count":38,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2021,1,30]]},"DOI":"10.1536\/ihj.20-458","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T22:13:24Z","timestamp":1611958404000},"page":"42-49","source":"Crossref","is-referenced-by-count":2,"title":["Early Vascular Response to Ultrathin Biodegradable Polymer Sirolimus-Eluting Stents for the Treatment of ST-Elevation Myocardial Infarction After Plaque Rupture"],"prefix":"10.1536","volume":"62","author":[{"given":"Yosuke","family":"Oishi","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Ogura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Legal Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Masaki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshiro","family":"Sakai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Sekimoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seita","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenari","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hitachi Medical Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kanto Rosai Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syunya","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Cardiac Catheterization Laboratories, Showa University Northern Yokohama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myong Hwa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Cardiac Catheterization Laboratories, Showa University Northern Yokohama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Kosaki","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, Showa University Koto-Toyosu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, Showa University Koto-Toyosu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikuo","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Koyama Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Koyama Memorial Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Cardiac Catheterization Laboratories, Showa University Northern Yokohama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Shinke","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Showa University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Sabate M, Cequier A, Iniguez A, <i>et al<\/i>. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380: 1482-90.","DOI":"10.1016\/S0140-6736(12)61223-9"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Kolandaivelu K, Swaminathan R, Gibson WJ, <i>et al<\/i>. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123: 1400-9.","DOI":"10.1161\/CIRCULATIONAHA.110.003210"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Morino Y, Terashita D, Otake H, <i>et al<\/i>. Early vascular responses to everolimus-eluting cobalt-chromium stent in the culprit lesions of st-elevation myocardial infarction: results from a multicenter prospective optical coherence tomography study (MECHANISM-AMI 2-week follow-up study). Cardiovasc Interv Ther 2019; 34: 14-24.","DOI":"10.1007\/s12928-017-0507-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kandzari DE, Mauri L, Koolen JJ, <i>et al<\/i>. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet 2017; 390: 1843-52.","DOI":"10.1016\/S0140-6736(17)32249-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Pilgrim T, Heg D, Roffi M, <i>et al<\/i>. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014; 384: 2111-22.","DOI":"10.1016\/S0140-6736(14)61038-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Iglesias JF, Muller O, Heg D, <i>et al<\/i>. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394: 1243-53.","DOI":"10.1016\/S0140-6736(19)31877-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Amabile N, Hammas S, Fradi S, <i>et al<\/i>. Intra-coronary thrombus evolution during acute coronary syndrome: regression assessment by serial optical coherence tomography analyses. Eur Heart J Cardiovasc Imaging 2015; 16: 433-40.","DOI":"10.1093\/ehjci\/jeu228"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hansi C, Arab A, Rzany A, Ahrens I, Bode C, Hehrlein C. Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. Catheter Cardiovasc Interv 2009; 73: 488-96.","DOI":"10.1002\/ccd.21834"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Otsuka F, Cheng Q, Yahagi K, <i>et al<\/i>. Acute thrombogenicity of a durable polymer everolimus-eluting stent relative to contemporary drug-eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc Interv 2015; 8: 1248-60.","DOI":"10.1016\/j.jcin.2015.03.029"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nakamura M, Yamagishi M, Ueno T, <i>et al<\/i>. Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry. Cardiovasc Interv Ther 2013; 28: 162-9.","DOI":"10.1007\/s12928-012-0146-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Matsumoto D, Shite J, Shinke T, <i>et al<\/i>. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J 2007; 28: 961-7.","DOI":"10.1093\/eurheartj\/ehl413"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ino Y, Kubo T, Tanaka A, <i>et al<\/i>. Comparison of vascular response between everolimus-eluting stent and bare metal stent implantation in ST-segment elevation myocardial infarction assessed by optical coherence tomography. Eur Heart J Cardiovasc Imaging 2015; 16: 513-20.","DOI":"10.1093\/ehjci\/jeu227"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sanuki Y, Sonoda S, Muraoka Y, <i>et al<\/i>. Contribution of poststent irregular protrusion to subsequent in-stent neoatherosclerosis after the second-generation drug-eluting stent implantation. Int Heart J 2018; 59: 307-14.","DOI":"10.1536\/ihj.17-463"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Thygesen K, Alpert JS, Jaffe AS, <i>et al<\/i>. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-35.","DOI":"10.1161\/CIR.0b013e31826e1058"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Karjalainen PP, Varho V, Nammas W, <i>et al<\/i>. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome-HATTRICK-OCT trial. Circ J 2015; 79: 360-7.","DOI":"10.1253\/circj.CJ-14-1000"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tearney GJ, Regar E, Akasaka T, <i>et al<\/i>. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012; 59: 1058-72.","DOI":"10.1016\/j.jacc.2011.09.079"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jia H, Abtahian F, Aguirre AD, <i>et al<\/i>. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol 2013; 62: 1748-58.","DOI":"10.1016\/j.jacc.2013.05.071"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shinke T, Itoh T, Ishida M, <i>et al<\/i>. Early and mid-term vascular responses to optical coherence tomography-guided everolimus-eluting stent implantation in stable coronary artery disease. Can J Cardiol 2019; 35: 1513-22.","DOI":"10.1016\/j.cjca.2019.07.633"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Soeda T, Uemura S, Park SJ, <i>et al<\/i>. Incidence and clinical significance of poststent optical coherence tomography findings: one-year follow-up study from a multicenter registry. Circulation 2015; 132: 1020-9.","DOI":"10.1161\/CIRCULATIONAHA.114.014704"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vascular Biol 2000; 20: 1262-75.","DOI":"10.1161\/01.ATV.20.5.1262"},{"key":"21","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","volume":"108","year":"2003","unstructured":"21. Naghavi M, Libby P, Falk E, <i>et al<\/i>. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-72.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Yonetsu T, Lee T, Murai T, <i>et al<\/i>. Plaque morphologies and the clinical prognosis of acute coronary syndrome caused by lesions with intact fibrous cap diagnosed by optical coherence tomography. Int J Cardiol 2016; 203: 766-74.","DOI":"10.1016\/j.ijcard.2015.11.030"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Niccoli G, Montone RA, Di Vito L, <i>et al<\/i>. Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. Eur Heart J 2015; 36: 1377-84.","DOI":"10.1093\/eurheartj\/ehv029"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Byrne RA, Serruys PW, Baumbach A, <i>et al<\/i>. Report of a European society of cardiology-European Association of Percutaneous Cardiovascular Interventions Task Force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 2015; 36: 2608-20.","DOI":"10.1093\/eurheartj\/ehv203"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gr\u00fcntzig Lecture ESC 2014. Eur Heart J 2015; 36: 3320-31.","DOI":"10.1093\/eurheartj\/ehv511"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. van Werkum JW, Heestermans AA, Zomer AC, <i>et al<\/i>. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399-409.","DOI":"10.1016\/j.jacc.2008.12.055"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Adriaenssens T, Joner M, Godschalk TC, <i>et al<\/i>. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). Circulation 2017; 136: 1007-21.","DOI":"10.1161\/CIRCULATIONAHA.117.026788"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Choi SY, Witzenbichler B, Maehara A, <i>et al<\/i>. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. Circ Cardiovasc Interv 2011; 4: 239-47.","DOI":"10.1161\/CIRCINTERVENTIONS.110.959791"},{"key":"29","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1161\/01.CIR.103.23.2816","volume":"103","year":"2001","unstructured":"29. Kastrati A, Mehilli J, Dirschinger J, <i>et al<\/i>. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-21.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Toledano Delgado FJ, Alvarez-Ossorio MP, de Lezo Cruz-Conde JS, <i>et al<\/i>. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent. Catheter Cardiovasc Interv 2014; 84: 720-6.","DOI":"10.1002\/ccd.25235"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Bangalore S, Toklu B, Patel N, <i>et al<\/i>. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation 2018; 138: 2216-26.","DOI":"10.1161\/CIRCULATIONAHA.118.034456"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Colombo A, Stankovic G, Moses JW. Selection of coronary stents. J Am Coll Cardiol 2002; 40: 1021-33.","DOI":"10.1016\/S0735-1097(02)02123-X"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Serruys PW, Suwannasom P, Nakatani S, Onuma Y. Snowshoe versus ice skate for scaffolding of disrupted vessel wall. JACC Cardiovasc Interv 2015; 8: 910-3.","DOI":"10.1016\/j.jcin.2015.04.005"},{"key":"34","unstructured":"34. Hehrlein C, Zimmermann M, Metz J, K\u00fcbler W. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron Artery Dis 1995; 6: 581-6."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Mauri L, Kereiakes DJ, Yeh RW, <i>et al<\/i>. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Eng J Med 2014; 371: 2155-66.","DOI":"10.1056\/NEJMoa1409312"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Mehran R, Baber U, Sharma SK, <i>et al<\/i>. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Eng J Med 2019; 381: 2032-42.","DOI":"10.1056\/NEJMoa1908419"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hahn JY, Song YB, Oh JH, <i>et al<\/i>. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial. JAMA 2019; 321: 2428-37.","DOI":"10.1001\/jama.2019.8146"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Watanabe H, Domei T, Morimoto T, <i>et al<\/i>. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321: 2414-27.","DOI":"10.1001\/jama.2019.8145"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/1\/62_20-458\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T03:58:32Z","timestamp":1611979112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/1\/62_20-458\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-458","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]}}}